JP2021533113A - 新規なマイオカイン及びその使用 - Google Patents

新規なマイオカイン及びその使用 Download PDF

Info

Publication number
JP2021533113A
JP2021533113A JP2021505195A JP2021505195A JP2021533113A JP 2021533113 A JP2021533113 A JP 2021533113A JP 2021505195 A JP2021505195 A JP 2021505195A JP 2021505195 A JP2021505195 A JP 2021505195A JP 2021533113 A JP2021533113 A JP 2021533113A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
acid sequence
muscle
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021505195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533113A5 (https=
JPWO2020026167A5 (https=
Inventor
ホフリング，ホルガー
ケラー，ハンスヨルグ
ルミール，ソフィー
サマーマター，サージ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021533113A publication Critical patent/JP2021533113A/ja
Publication of JP2021533113A5 publication Critical patent/JP2021533113A5/ja
Publication of JPWO2020026167A5 publication Critical patent/JPWO2020026167A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021505195A 2018-08-02 2019-07-31 新規なマイオカイン及びその使用 Pending JP2021533113A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187131.0 2018-08-02
EP18187131 2018-08-02
PCT/IB2019/056537 WO2020026167A1 (en) 2018-08-02 2019-07-31 New myokines and uses thereof

Publications (3)

Publication Number Publication Date
JP2021533113A true JP2021533113A (ja) 2021-12-02
JP2021533113A5 JP2021533113A5 (https=) 2022-08-08
JPWO2020026167A5 JPWO2020026167A5 (https=) 2022-08-08

Family

ID=63144838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505195A Pending JP2021533113A (ja) 2018-08-02 2019-07-31 新規なマイオカイン及びその使用

Country Status (10)

Country Link
US (1) US20220144908A1 (https=)
EP (1) EP3829620B1 (https=)
JP (1) JP2021533113A (https=)
KR (1) KR20210041580A (https=)
CN (1) CN112512553A (https=)
AU (1) AU2019313506A1 (https=)
CA (1) CA3106518A1 (https=)
IL (1) IL280369A (https=)
TW (1) TW202019457A (https=)
WO (1) WO2020026167A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004532A2 (en) * 2001-07-05 2003-01-16 Geneprot, Inc. Q9ul33/q9nzz4 and q9h5p3 splice variants
JP2004313167A (ja) * 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522239A (ja) 1997-03-21 2001-11-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ８７個のヒト分泌タンパク質
JP2003502004A (ja) 1997-10-02 2003-01-21 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004532A2 (en) * 2001-07-05 2003-01-16 Geneprot, Inc. Q9ul33/q9nzz4 and q9h5p3 splice variants
JP2004313167A (ja) * 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Evaluating the Impact of Novel Bone Marrow Cell-secreted Factors, C19orf10 and C1orf54, on Immunomod", A THESIS SUBMITTED IN CONFORMITY WITH THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE INSTITUTE, JPN7023002581, 2017, pages 1 - 149, ISSN: 0005269861 *
J CELL MOL MED., vol. 22, JPN6023027714, 12 July 2018 (2018-07-12), pages 4985 - 4996, ISSN: 0005269860 *

Also Published As

Publication number Publication date
US20220144908A1 (en) 2022-05-12
AU2019313506A1 (en) 2021-01-14
CA3106518A1 (en) 2020-02-06
IL280369A (en) 2021-03-01
TW202019457A (zh) 2020-06-01
CN112512553A (zh) 2021-03-16
KR20210041580A (ko) 2021-04-15
EP3829620A1 (en) 2021-06-09
WO2020026167A1 (en) 2020-02-06
EP3829620B1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
JP7829511B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
CN108472336B (zh) C型利尿钠肽变体在治疗骨骼发育不良中的用途
JP6363952B2 (ja) 成長ホルモン断片の使用
US20190060419A1 (en) Methods for treating hypophosphatasia in adolescents and adults
EA035158B1 (ru) Пептиды и композиции для лечения повреждений суставов
KR20160029110A (ko) 양이온성 신경독소
KR20190129058A (ko) 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2023116739A (ja) Ａｐｏｃ－ｉｉ模倣ペプチド
EP3829620B1 (en) New myokines and uses thereof
JP7624240B2 (ja) 脊髄性筋萎縮症を治療する方法及び薬剤
US10729746B2 (en) Recombinant placenta growth factor for treating Duchenne muscular dystrophy
MXPA06000954A (es) Uso de hormona del crecimiento humano en atrofia de multiples sistemas.
US20220143218A1 (en) Methods of treating or preventing age-related disorders
JP2019525931A (ja) ヒト成長ホルモンアナログによる成人成長ホルモン欠乏症の処置
CN116744958A (zh) 骨关节炎疼痛的治疗
EA042134B1 (ru) МИМЕТИЧЕСКИЕ ПЕПТИДЫ apoC-II

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022